IL-23R Gene Variants and Autoimmune Disease Risk

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on genetics & immunity. Browse all Genetics & Immunity education

The interleukin-23 receptor, encoded by the IL23R gene, sits at a control point of the immune system that has become one of the most important stories in autoimmune genetics. When IL-23R signaling runs too hot, it fuels a branch of immunity that drives chronic inflammation — and variants in this single gene shift risk across several distinct autoimmune diseases at once.

What IL-23R does

IL-23R is the docking site for interleukin-23, a signaling protein that sustains a population of immune cells called Th17 cells. Once activated, Th17 cells pump out interleukin-17 and related molecules that recruit inflammation to barrier tissues such as the gut, skin, and joints. This IL-23/IL-17 axis is protective against certain infections, but when it stays switched on it becomes a central driver of autoimmune tissue damage. That is why the receptor has become a major drug target in modern immunology.

Autoimmune diseases linked to altered IL-23R function

Genetic variation in IL23R has been associated with a striking cluster of conditions: inflammatory bowel disease (both Crohn's disease and ulcerative colitis), psoriasis, ankylosing spondylitis, and psoriatic arthritis. These diseases affect different organs but share the same underlying immune wiring, which is why they often run together in families and respond to therapies aimed at the same pathway. IL23R is a textbook example of one gene influencing many seemingly separate autoimmune conditions through a shared mechanism.

The key variant: rs11209026 (Arg381Gln)

The best-characterized IL23R variant is rs11209026, which swaps arginine for glutamine at position 381 (the R381Q change). Unusually, the minority form of this variant is protective — it dampens IL-23 signaling and is associated with lower risk of Crohn's disease, psoriasis, and ankylosing spondylitis. This was one of the first findings to show that turning IL-23R signaling down reduces autoimmune risk, a discovery that helped validate the entire pathway as a therapeutic target.

What the research shows

Genome-wide association studies across large patient populations have repeatedly confirmed the link between IL23R variants and this family of immune-mediated diseases, and the protective rs11209026 signal has been replicated many times. The strength of that evidence is part of why biologic therapies targeting IL-23 and IL-17 were developed. The genetics did not just describe risk — it pointed directly at a mechanism that could be modulated under medical care.

What your PlexusDx results reveal

For an immune topic like this one, the informative signal is IL23R and its Th17-pathway partners rather than unrelated markers. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across your DNA, giving you pathway-level context about how your body is wired. It is a map, not a verdict: your genotype does not change, but knowing it can sharpen the questions you bring to a qualified healthcare provider. The test reports on your biology — it does not tell you what to put in your body, diagnose a condition, or predict how you will respond to any specific medication.

What to do with the information

Carrying a risk-associated IL23R variant does not mean you have or will develop an autoimmune disease — most carriers never do, and protective variants exist too. If you have a personal or family history of IBD, psoriasis, or spondyloarthritis, the productive move is to share it with a qualified provider, who can weigh symptoms, exams, and appropriate testing. Genetic context can make that conversation more informed; it does not diagnose, treat, or manage any of these conditions on its own.

Frequently Asked Questions

Which autoimmune diseases are linked to IL-23R?

IL23R variants are associated with inflammatory bowel disease (Crohn's and ulcerative colitis), psoriasis, ankylosing spondylitis, and psoriatic arthritis. These conditions share the IL-23/IL-17 immune pathway, which is why one gene influences several of them. A genetic association reflects risk, not a diagnosis, and requires a qualified provider to interpret.

Is the IL23R rs11209026 variant harmful?

The opposite, in most cases. The minority form of rs11209026 (Arg381Gln) dampens IL-23 signaling and is protective — it is linked to lower risk of Crohn's disease, psoriasis, and ankylosing spondylitis. Genetics here is a map of tendencies, not a verdict about whether you will develop any condition.

Can a genetic test diagnose my autoimmune condition?

No. The Precision Peptide Genetic Test offers pathway-level context, not a diagnosis. It analyzes immune-signaling genes to describe how your biology is wired. Diagnosing psoriasis, IBD, or spondyloarthritis requires clinical evaluation, exams, and testing performed by a qualified healthcare provider.

If I carry an IL23R risk variant, what should I do?

Share your personal and family history with a qualified provider. Carrying a risk variant does not mean disease is certain — most carriers stay healthy. A clinician can weigh your symptoms and decide whether monitoring or further testing is appropriate. Genetic insight informs that conversation rather than replacing it.

Want pathway-level context on your own immune signaling pathways? The Precision Peptide Genetic Test translates your DNA into insights you can review with a qualified provider — education about your biology, not a diagnosis.

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use, and it does not diagnose, treat, or prevent any disease. Consult a qualified healthcare provider before beginning any peptide protocol.

This article is part of the PlexusDx Education Hub. Browse all Genetics & Immunity education